Cancer

World Class Health Secures $8M in Seed Funding to Expand Concierge Health Benefit with the largest Global Centers of Excellence network

World Class Health's pioneering benefit has achieved a stellar 1.6% readmission rate and delivered a 90+ NPS from nearly 4,000…

17 hours ago

Nature Publication Supports Senolytic Approach for Cancer Treatment

"Senolytic Immunotherapy" is the basis of Immorta Bio's first-in-class oncology platform MIAMI BEACH, Fla., Nov. 20, 2024 /PRNewswire/ -- A…

17 hours ago

Partsol Introduces Revolutionary AI Stem Cell Technology to Transform Cognitive AI

TAMPA, Fla., Nov. 20, 2024 /PRNewswire/ -- Partsol, the global leader in Cognitive AI and creator of the proprietary Absolute Truth…

17 hours ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to…

20 hours ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi)…

20 hours ago

Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Celularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia…

20 hours ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical…

20 hours ago

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials…

20 hours ago